To identify and follow blood vessel-related changes in the brain that contribute to cognitive impairment and dementia, researchers and clinicians typically rely on MRI to evaluate 'downstream' biological markers -- those at the end of a cascade of events. But a new multicenter study could lead to a cost-effective blood test to identify changes occurring near the top of the chain, potentially identifying at-risk patients at an earlier stage.
